$9.63
1.43% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Amicus Therapeutics, Inc. Stock price

$9.63
-0.33 3.31% 1M
-0.28 2.83% 6M
-4.56 32.14% YTD
-4.80 33.26% 1Y
-2.44 20.22% 3Y
-0.11 1.13% 5Y
+1.33 16.02% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.14 1.43%
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Key metrics

Market capitalization $2.88b
Enterprise Value $3.07b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.22
P/S ratio (TTM) P/S ratio 5.83
P/B ratio (TTM) P/B ratio 16.08
Revenue growth (TTM) Revenue growth 32.58%
Revenue (TTM) Revenue $493.67m
EBIT (operating result TTM) EBIT $14.40m
Free Cash Flow (TTM) Free Cash Flow $-31.51m
Cash position $249.76m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 5.47
EV/Sales forward 5.84
Short interest 7.01%
Show more

Is Amicus Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Amicus Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Amicus Therapeutics, Inc. forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a Amicus Therapeutics, Inc. forecast:

Buy
77%
Hold
23%

Financial data from Amicus Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
494 494
33% 33%
100%
- Direct Costs 58 58
37% 37%
12%
436 436
32% 32%
88%
- Selling and Administrative Expenses 298 298
18% 18%
60%
- Research and Development Expense 114 114
37% 37%
23%
23 23
122% 122%
5%
- Depreciation and Amortization 8.69 8.69
24% 24%
2%
EBIT (Operating Income) EBIT 14 14
113% 113%
3%
Net Profit -105 -105
40% 40%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Amicus Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amicus Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold dominates its market segment, and a licensing deal with Teva de-risks future growth, positioning it for a continued revenue increase.
Neutral
GlobeNewsWire
5 days ago
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association
Neutral
GlobeNewsWire
10 days ago
Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.
More Amicus Therapeutics, Inc. News

Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Head office United States
CEO Bradley Campbell
Employees 517
Founded 2002
Website www.amicusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today